pmid	doi	year	title	Hugo_Symbol
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	MYC
33779481	10.1080/01676830.2021.1904426	2022	Double-hit and triple-hit high-grade B-cell lymphoma of the ocular adnexa.	MYC
33782541	10.1038/s41401-021-00644-1	2022	SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.	MYC
33908607	10.1182/blood.2020007932	2022	MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress.	MYC
34131801	10.1007/s00432-021-03691-7	2022	Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma.	MYC
34162177	10.3324/haematol.2020.267096	2022	Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.	MYC
34162179	10.3324/haematol.2021.278743	2022	Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.	MYC
34219494	10.1177/00031348211029854	2022	Burkitt Lymphoma Presenting as Perforated Appendicitis.	MYC
34289655	10.3324/haematol.2021.278638	2022	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.	MYC
34304248	10.1038/s41375-021-01347-6	2022	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.	MYC
34359075	10.1182/blood.2021012805	2022	Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.	MYC
34392269	10.1097/PAS.0000000000001750	2022	Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.	MYC
34456240	10.1097/PAI.0000000000000967	2022	Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.	MYC
34471258	10.1038/s41416-021-01538-z	2022	Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma.	MYC
34472720	10.1002/cnr2.1545	2022	Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	MYC
34476551	10.1007/s00259-021-05498-7	2022	Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements.	MYC
34493477	10.1016/j.clml.2021.07.017	2022	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.	MYC
34510996	10.1080/10428194.2021.1975189	2022	<i>BCL2</i> translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival.	MYC
34519021	10.1111/bjh.17815	2022	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.	MYC
34525177	10.1182/blood.2020008374	2022	Defining and treating high-grade B-cell lymphoma, NOS.	MYC
34528662	10.1093/ajcp/aqab105	2022	MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.	MYC
34535296	10.1016/j.pathol.2021.06.121	2022	High-grade B-cell lymphoma with concurrent expression of CD5 and cyclin D1 and MYC rearrangement.	MYC
34536035	10.1111/cup.14135	2022	Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee.	MYC
34559466	10.1111/ijlh.13709	2022	Discordant high-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a pericardial effusion.	MYC
34601571	10.1182/blood.2021013156	2022	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.	MYC
34608246	10.1038/s41379-021-00909-4	2022	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.	MYC
34612761	10.1080/10428194.2021.1986218	2022	Plasmablastic lymphomas show restricted EBV latency profile and <i>MYC</i> gene aberrations.	MYC
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	MYC
34632715	10.1002/1878-0261.13115	2022	Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma.	MYC
34637146	10.1111/his.14585	2022	EBV<sup>+</sup> high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study.	MYC
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	MYC
34668039	10.1007/s00262-021-03057-5	2022	CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein-Barr virus genes.	MYC
34668583	10.1002/eji.202149355	2022	MALT1 protease function in regulatory T cells induces MYC activity to promote mitochondrial function and cellular expansion.	MYC
34669156	10.1007/s11684-021-0877-y	2022	Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.	MYC
34688842	10.1016/j.canlet.2021.10.022	2022	Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.	MYC
34698964	10.1007/s10637-021-01196-1	2022	FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells.	MYC
34706126	10.1111/cas.15179	2022	High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.	MYC
34711640	10.1158/2159-8290.CD-21-0551	2022	Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia.	MYC
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	MYC
34727403	10.1111/pin.13182	2022	AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	MYC
34727830	10.1080/10428194.2021.1998480	2022	Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.	MYC
34728235	10.1016/j.bbamcr.2021.119168	2022	DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication.	MYC
34739417	10.1097/PAS.0000000000001830	2022	Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma.	MYC
34764434	10.1038/s41379-021-00962-z	2022	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.	MYC
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	MYC
34842019	10.1080/10428194.2021.2008383	2022	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	MYC
34861448	10.1016/j.wneu.2021.11.108	2022	Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.	MYC
34872752	10.1016/j.pathol.2021.09.009	2022	EBV-positive low-grade follicular lymphoma transforming to EBV-negative high-grade B-cell lymphoma with MYC and BCL2 rearrangements.	MYC
34875555	10.1016/j.leukres.2021.106769	2022	MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1).	MYC
34882582	10.1172/JCI153283	2022	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.	MYC
34903527	10.1101/gr.275911.121	2022	Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers.	MYC
34910327	10.1111/jop.13269	2022	Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases.	MYC
34951009	10.1111/bjh.17971	2022	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.	MYC
34954522	10.1016/j.bbrc.2021.12.063	2022	The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.	MYC
34962105	10.1002/dc.24922	2022	Primary thyroid high-grade B-cell lymphoma with MYC and BCL2 rearrangements in Hashimoto's thyroiditis.	MYC
34971957	10.1016/j.bbrc.2021.12.078	2022	CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.	MYC
34975070	10.4103/aja2021114	2022	Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells.	MYC
34980601	10.1158/1078-0432.CCR-21-2949	2022	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.	MYC
34983615	10.1186/s13046-021-02226-9	2022	SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma.	MYC
34997652	10.1111/ejh.13736	2022	Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.	MYC
35013138	10.1038/s41420-021-00622-w	2022	Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis.	MYC
35019715	10.1128/jvi.01941-21	2022	Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.	MYC
35020836	10.1182/blood.2021012077	2022	Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.	MYC
35022408	10.1038/s41467-021-27704-8	2022	Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.	MYC
35030628	10.1182/bloodadvances.2021005948	2022	Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma.	MYC
35031886	10.1186/s43556-021-00066-9	2022	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.	MYC
35036912	10.1177/2632010X211070774	2022	Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.	MYC
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	MYC
35046056	10.1158/1078-0432.CCR-21-3617	2022	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.	MYC
35054466	10.3390/life12010073	2022	The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.	MYC
35069971	10.1155/2022/3334522	2022	Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.	MYC
35075986	10.1080/10428194.2021.2008381	2022	RNA-binding proteins as drivers of AML and novel therapeutic targets.	MYC
35078195	10.1159/000520723	2022	The Expression of the RUVBL1 Component of the R2TP Complex Correlates with Poor Prognosis in DLBCL.	MYC
35082399	10.1038/s41417-021-00415-4	2022	CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.	MYC
35091546	10.1038/s41420-022-00833-9	2022	Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.	MYC
35091678	10.1038/s41388-021-02162-0	2022	An mRNA expression-based signature for oncogene-induced replication-stress.	MYC
35114276	10.1016/j.gene.2022.146234	2022	Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma.	MYC
35123209	10.1016/j.esmoop.2021.100337	2022	Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.	MYC
35125708	10.1007/s12288-021-01427-8	2022	Comparison Between CHOP and DAEPOCH with or Without Rituximab in Adult High Grade B Cell Lymphoma, Not Otherwise Specified; A Retrospective Study From a Tertiary Cancer Hospital in South India.	MYC
35126914	10.1155/2022/2842066	2022	Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis.	MYC
35132576	10.1007/s12519-022-00517-5	2022	ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.	MYC
35135797	10.1136/bcr-2021-246687	2022	Burkitt lymphoma: interpreting FISH testing for <i>MYC</i> gene rearrangements.	MYC
35139388	10.1016/j.celrep.2022.110338	2022	The spliceosome component Usp39 controls B cell development by regulating immunoglobulin gene rearrangement.	MYC
35145347	10.1016/j.jsps.2021.12.009	2022	Reposition of the anti-inflammatory drug diacerein in an <i>in-vivo</i> colorectal cancer model.	MYC
35149590	10.1158/0008-5472.CAN-21-1168	2022	Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy.	MYC
35152630	10.3760/cma.j.cn112151-20210826-00604	2022	[Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].	MYC
35167621	10.1371/journal.pone.0263980	2022	Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature.	MYC
35169547	10.4102/ajlm.v11i1.1355	2022	Extranodal presentation of a lymphoma with precursor B-cell phenotype and translocation t(8;14) in South Africa.	MYC
35171885	10.1097/DAD.0000000000002077	2022	A Case of CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type Secondary to Chronic Lymphedema.	MYC
35173274	10.1038/s41375-022-01516-1	2022	Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.	MYC
35174018	10.7759/cureus.21208	2022	A Conservative Approach to the Treatment of a Rare Case of Cervical Spine Double Expressor Diffuse Large B-cell Lymphoma: A Case Report.	MYC
35183824	10.1016/j.prp.2022.153804	2022	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.	MYC
35185889	10.3389/fimmu.2022.797244	2022	Calcium Signaling Is Impaired in PTEN-Deficient T Cell Acute Lymphoblastic Leukemia.	MYC
35198451	10.3389/fonc.2022.834288	2022	Prognostic Value of Radiomic Features of <sup>18</sup>F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.	MYC
35205272	10.3390/genes13020227	2022	The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.	MYC
35216159	10.3390/ijms23042044	2022	IBtkα Activates the β-Catenin-Dependent Transcription of <i>MYC</i> through Ubiquitylation and Proteasomal Degradation of GSK3β in Cancerous B Cells.	MYC
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	MYC
35231992	10.3760/cma.j.issn.0253-2727.2022.01.009	2022	[MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].	MYC
35245453	10.1016/j.molcel.2022.02.015	2022	How to resist Notch-targeted T-leukemia therapy: Lineage- and MYC enhancer switch.	MYC
35246617	10.1038/s41388-022-02257-2	2022	Alcohol-driven metabolic reprogramming promotes development of RORγt-deficient thymic lymphoma.	MYC
35247891	10.1158/2159-8290.CD-21-1207	2022	Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma.	MYC
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	MYC
35260179	10.1186/s13046-022-02276-7	2022	A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.	MYC
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	MYC
35267654	10.3390/cancers14051346	2022	Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma.	MYC
35277463	10.1136/jitc-2020-002029corr1	2022	Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	MYC
35279534	10.1016/j.theriogenology.2022.02.028	2022	Ascorbic acid regulates mouse spermatogonial stem cell proliferation in a Wnt/β-catenin/ROS signaling dependent manner.	MYC
35289116	10.1002/cjp2.266	2022	CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.	MYC
35295953	10.3389/fgene.2022.825901	2022	<i>MCTS1</i> as a Novel Prognostic Biomarker and Its Correlation With Immune Infiltrates in Breast Cancer.	MYC
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	MYC
35297566	10.1111/pin.13223	2022	Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.	MYC
35299080	10.1016/j.anndiagpath.2022.151913	2022	HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies.	MYC
35303910	10.1186/s13045-022-01249-9	2022	Altered pathways and targeted therapy in double hit lymphoma.	MYC
35306137	10.1016/j.cellsig.2022.110311	2022	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.	MYC
35309974	10.1016/j.rmcr.2022.101625	2022	A case of lung intravascular large B cell lymphoma developed with respiratory failure rescued by corticosteroid prior to definite diagnosis.	MYC
35316216	10.1172/JCI153436	2022	PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.	MYC
35321274	10.4251/wjgo.v14.i3.746	2022	Re: Association between intestinal neoplasms and celiac disease - beyond celiac disease and more.	MYC
35328502	10.3390/ijms23063079	2022	Mono a Mano: ZBP1's Love-Hate Relationship with the Kissing Virus.	MYC
35332847	10.1080/15384047.2022.2055421	2022	Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells.	MYC
35338347	10.1038/s41417-022-00450-9	2022	SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.	MYC
35380701	10.1158/1541-7786.MCR-21-0560	2022	T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62.	MYC
35395974	10.19746/j.cnki.issn.1009-2137.2022.02.017	2022	[Expression Level and Correlation of miR-211, miR-155, C-myc in Acute T Lymphocytic Leukemia].	MYC
35398498	10.1016/j.jep.2022.115267	2022	Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.	MYC
35411936	10.1111/bjh.18196	2022	Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1α intersect to regulate angiogenesis in B-cell lymphoma.	MYC
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	MYC
35414839		2022	Primary ovarian Burkitt lymphoma: report of a case and review of literature.	MYC
35429891	10.1016/j.prp.2022.153860	2022	The genetic deletion and protein expression of PRDM1 and its clinical implications in diffuse large B cell lymphoma: A retrospective cohort study in China.	MYC
35443279	10.1158/2159-8290.CD-21-1514	2022	SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis.	MYC
35444774	10.4084/MJHID.2022.018	2022	TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.	MYC
35447911	10.3390/md20040235	2022	5-<i>O</i>-(<i>N</i>-Boc-l-Alanine)-Renieramycin T Induces Cancer Stem Cell Apoptosis via Targeting Akt Signaling.	MYC
35453482	10.3390/biomedicines10040731	2022	Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells.	MYC
35454765	10.3390/cancers14081857	2022	Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.	MYC
35477814	10.1007/s10637-022-01250-6	2022	Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.	MYC
35481444	10.1080/10428194.2022.2064988	2022	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.	MYC
35481805	10.1080/10428194.2022.2064989	2022	Homozygous iMycCα transgenic mice as a model of plasma B-cell lymphomas.	MYC
35482553	10.1002/hon.3010	2022	Targeting MYC and BCL2 by a natural compound for ""double-hit"" lymphoma.	MYC
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	MYC
35486832	10.1182/blood.2021013990	2022	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.	MYC
35489963	10.1016/j.blre.2022.100967	2022	ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.	MYC
35498426	10.3389/fendo.2022.846357	2022	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.	MYC
35503708	10.1080/10428194.2022.2064981	2022	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.	MYC
35503749	10.1002/eji.202249820	2022	Epstein-Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only AID seems to play a major mutagenic role in Burkitt lymphoma.	MYC
35510016	10.7759/cureus.23681	2022	Incidental Pathogenic Fibrin-Associated Diffuse Large B-cell Lymphoma Found During Aorto-Biiliac Bypass.	MYC
35510955	10.15252/emmm.202215816	2022	A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.	MYC
35511691	10.1093/ajcp/aqac047	2022	A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.	MYC
35512442	10.1016/j.leukres.2022.106843	2022	Multiple cells of origin in common with various types of mouse N-Myc acute leukemia.	MYC
35523507	10.1136/bcr-2021-247430	2022	Epstein-Barr virus-positive mucocutaneous ulcer, plasmablastic type, associated with nodal CD4+ angioimmunoblastic T-cell lymphoma and generalised pruritus: a self-limiting lymphoproliferative disorder resembling cutaneous plasmablastic lymphoma.	MYC
35534379	10.1016/j.clml.2022.04.009	2022	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.	MYC
35538643	10.1002/cam4.4742	2022	Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.	MYC
35539018	10.1016/j.lrr.2022.100318	2022	A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement.	MYC
35562413	10.1038/s41379-022-01091-x	2022	Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.	MYC
35563017	10.3390/ijms23094624	2022	Enhancer RNA AL928768.3 from the IGH Locus Regulates MYC Expression and Controls the Proliferation and Chemoresistance of Burkitt Lymphoma Cells with IGH/MYC Translocation.	MYC
35578798	10.1002/jcp.30777	2022	Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells.	MYC
35580327	10.1182/bloodadvances.2022007475	2022	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.	MYC
35581375	10.1038/s41375-022-01590-5	2022	Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia.	MYC
35583405	10.1097/DAD.0000000000002053	2022	Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma.	MYC
35591851	10.3389/fgene.2022.873840	2022	Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells.	MYC
35595618	10.1016/j.clml.2022.04.010	2022	Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.	MYC
35605249	10.1182/bloodadvances.2022007695	2022	Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.	MYC
35620830	10.1111/bjh.18280	2022	Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience.	MYC
35622737	10.3390/vetsci9050209	2022	<i>IL-1R8</i> Downregulation and Concomitant <i>TLR7</i> and <i>TLR9</i> Upregulation Are Related to the Pathogenesis of Canine Diffuse Large B-Cell Lymphoma.	MYC
35650679	10.1097/PAS.0000000000001923	2022	Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma.	MYC
35652622	10.4149/neo_2022_220318N300	2022	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.	MYC
35657404	10.1007/s00428-022-03342-3	2022	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.	MYC
35670760	10.1002/pbc.29804	2022	Discordance between detection of MYC rearrangement by immunohistochemistry versus fluorescent in situ hybridization in Burkitt lymphoma.	MYC
35673721	10.3760/cma.j.cn112151-20211117-00836	2022	[ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases].	MYC
35681778	10.3390/cancers14112799	2022	The Role of NOTCH1, GATA3, and c-MYC in T Cell Non-Hodgkin Lymphomas.	MYC
35696785	10.1016/j.biomaterials.2022.121607	2022	Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma.	MYC
35705274	10.2169/internalmedicine.9711-22	2022	Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and BCL2.	MYC
35708139	10.3324/haematol.2022.281226	2022	Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.	MYC
35715938	10.1002/cjp2.283	2022	Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.	MYC
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	MYC
35740961	10.3390/biom12060836	2022	Alternative <i>c-MYC</i> mRNA Transcripts as an Additional Tool for c-Myc2 and c-MycS Production in BL60 Tumors.	MYC
35757978	10.1002/jbt.23117	2022	l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.	MYC
35761419	10.1186/s40164-022-00292-z	2022	Targeting metabolic reprogramming in chronic lymphocytic leukemia.	MYC
35766067	10.1684/abc.2022.1713	2022	Looking for the truth: an IGH-MYC+ lymphoid neoplasm with immature B-cell phenotype (CD34 positivity) successfully treated with Burkitt lymphoma protocol.	MYC
35774514	10.3389/fgene.2022.827840	2022	A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.	MYC
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	MYC
35777795		2022	PLAGL2 Promotes the Proliferation and Migration of Diffuse Large B-cell Lymphoma Cells via Wnt/β-catenin Pathway.	MYC
35787399	10.1016/j.jid.2022.06.005	2022	The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.	MYC
35789258	10.1182/blood.2022015674	2022	Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B cell malignancy.	MYC
35790817	10.1038/s41375-022-01626-w	2022	Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia.	MYC
35794797	10.4062/biomolther.2022.022	2022	CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy.	MYC
35800829	10.7759/cureus.25547	2022	Diagnosis of Primary Hepatic Lymphoma in a 55-Year-Old Male Patient Presented With Pain in the Right Hypochondrium: A Very Rare Case.	MYC
35815807	10.1158/0008-5472.CAN-21-2454	2022	The X-Linked Helicase DDX3X Is Required for Lymphoid Differentiation and MYC-Driven Lymphomagenesis.	MYC
35829664	10.1111/bjh.18352	2022	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.	MYC
35836517	10.21037/tcr-21-1692	2022	Effects of heavy ions (<sup>12</sup>C<sup>6+</sup>) on malignant melanoma B16F10 cells.	MYC
35846201	10.1002/jha2.310	2022	Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.	MYC
35846216	10.1002/jha2.364	2022	Primary cutaneous diffuse large B-cell lymphoma, leg type with <i>MYC/BCL2/BCL6</i> overexpression.	MYC
35847943	10.3389/fonc.2022.925666	2022	Glutor, a Glucose Transporter Inhibitor, Exerts Antineoplastic Action on Tumor Cells of Thymic Origin: Implication of Modulated Metabolism, Survival, Oxidative Stress, Mitochondrial Membrane Potential, pH Homeostasis, and Chemosensitivity.	MYC
35851125	10.19540/j.cnki.cjcmm.20220309.401	2022	[Paeoniflorin induces apoptosis and cycle arrest in B-cell acute lymphoblastic leukemia cells by inhibiting SENP1/c-Myc signaling pathway].	MYC
35866590	10.1093/hmg/ddac159	2022	The lncRNA KTN1-AS1 co-regulates a variety of Myc-target genes and enhances proliferation of Burkitt lymphoma cells.	MYC
35869021	10.1016/j.clml.2022.06.011	2022	Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.	MYC
35878052	10.18388/abp.2020_5833	2022	The clinicopathological characteristics of C-MYC protein in angioimmunoblastic T-cell lymphoma.	MYC
35879400	10.1038/s41598-022-16943-4	2022	Promising anti-leukemic effect of Zataria multiflora extract in combination with doxorubicin to combat acute lymphoblastic leukemia cells (Nalm-6) (in vitro and in silico).	MYC
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	MYC
35884496	10.3390/cancers14143434	2022	Classifying Germinal Center Derived Lymphomas-Navigate a Complex Transcriptional Landscape.	MYC
35885931	10.3390/genes13071144	2022	Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group.	MYC
35897737	10.3390/ijms23158161	2022	The Pt(<i>S</i>-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.	MYC
35899960	10.2174/1871520622666220722105802	2022	Galbanic acid improves accumulation and toxicity of arsenic trioxide in MT-2 cells.	MYC
35900784	10.1182/blood.2022016280	2022	EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.	MYC
35911113	10.3389/fnut.2022.907386	2022	Selenium Nanoparticles Improved Intestinal Health Through Modulation of the NLRP3 Signaling Pathway.	MYC
35912172	10.3389/fonc.2022.896858	2022	Recurrent Novel <i>P2RY8/IGH</i> Translocations in B-Lymphoblastic Leukemia/Lymphoma.	MYC
35916333	10.1002/dc.25027	2022	HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.	MYC
35916644	10.1097/QAI.0000000000003069	2022	Diffuse Large B-cell Lymphoma in the public-sector of Johannesburg, South Africa, in the era of widescale Anti-retroviral therapy use.	MYC
35918411	10.1038/s41401-022-00936-0	2022	Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain.	MYC
35920412	10.1002/jbt.23185	2022	Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro.	MYC
35921443	10.1073/pnas.2201493119	2022	Tcf-1 promotes genomic instability and T cell transformation in response to aberrant β-catenin activation.	MYC
35932211	10.1002/hon.3061	2022	Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.	MYC
35932292	10.1002/cncr.34405	2022	Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.	MYC
35943680	10.1007/s11596-022-2612-6	2022	PHOSPHO1 Serves as a Key Metabolism-Related Biomarker in the Tumorigenesis of Diffuse Large B-cell Lymphoma.	MYC
35945217	10.1038/s41467-022-32368-z	2022	MYC sensitises cells to apoptosis by driving energetic demand.	MYC
35952327	10.1200/JCO.22.00597	2022	Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.	MYC
35952646	10.1016/j.chom.2022.07.003	2022	Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis.	MYC
35953760	10.1631/jzus.B2200016	2022	HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.	MYC
35960849	10.1182/blood.2022016428	2022	Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma.	MYC
35961968	10.1038/s41467-022-32485-9	2022	Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.	MYC
35963941	10.1038/s41375-022-01658-2	2022	Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.	MYC
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	MYC
35969234	10.1158/2326-6066.CIR-21-0813	2022	TCR-independent metabolic reprogramming precedes lymphoma-driven changes in T-cell fate.	MYC
35975515	10.7754/Clin.Lab.2021.211028	2022	Disparity Analysis of Clinicopathologic Hallmarks between Transformed DLBCL and Primary DLBCL.	MYC
35978743	10.7759/cureus.26860	2022	Sporadic Burkitt Lymphoma of the Thoracic and Lumbar Spinal Canal in an Adult: Oncogenicity and a Literature Review.	MYC
35981367	10.19746/j.cnki.issn.1009-2137.2022.04.018	2022	[Effects of BET Bromodomain Inhibitor JQ1 on Double-Expressor Lymphoma Cell Lines and Its Mechanism].	MYC
36001789	10.46883/2022.25920970	2022	Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.	MYC
36006771	10.1097/PAS.0000000000001957	2022	Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study.	MYC
36012375	10.3390/ijms23169113	2022	Concomitant Inhibition of IRE1α/XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas.	MYC
36040107	10.1002/JLB.6MA0822-720RR	2022	Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study.	MYC
36051032	10.1002/jha2.451	2022	An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts <i>MYC</i> rearrangements in large B-cell lymphoma.	MYC
36051037	10.1002/jha2.475	2022	B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.	MYC
36051039	10.1002/jha2.513	2022	Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement.	MYC
36051055	10.1002/jha2.457	2022	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.	MYC
36057749	10.1007/s00428-022-03404-6	2022	Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.	MYC
36068335	10.1038/s41388-022-02450-3	2022	Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition.	MYC
36069512	10.1080/00015458.2022.2122320	2022	Diffuse large B-cell lymphoma presenting as an inguinal hernia - case report.	MYC
36074710	10.1111/ijlh.13863	2022	Plasmablastic lymphoma: An update.	MYC
36075025	10.1182/bloodadvances.2022007849	2022	Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels.	MYC
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	MYC
36088477	10.1038/s41379-022-01150-3	2022	Double/triple hit lymphoma in the gastrointestinal tract: clinicopathological features, PD-L1 expression and screening strategy.	MYC
32273477	10.3324/haematol.2019.243071	2021	<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma.	MYC
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	MYC
33120427	10.1182/blood.2020007193	2021	The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.	MYC
33300153	10.1002/hon.2831	2021	Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.	MYC
33303632	10.1074/jbc.RA120.015285	2021	A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation.	MYC
33306213	10.1002/ajh.26068	2021	First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.	MYC
33310759	10.26508/lsa.202000794	2021	Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis.	MYC
33311588	10.1038/s41416-020-01180-1	2021	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.	MYC
33340851	10.1016/j.leukres.2020.106491	2021	Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia.	MYC
33360122	10.1016/j.cancergen.2020.12.004	2021	RNA-Based next generation sequencing complements but does not replace fluorescence in situ hybridization studies for the classification of aggressive B-Cell lymphomas.	MYC
33380460	10.1136/jclinpath-2020-207121	2021	Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study.	MYC
33392349	10.22038/AOJNMB.2020.48887.1332	2021	Incremental Value of FDG PET/CT in Aggressive High Grade B Cell lymphoma with TdT Expression.	MYC
33393079	10.1111/his.14327	2021	Radiologically guided percutaneous core needle biopsy of the spleen: a reliable and safe diagnostic procedure for neoplastic and reactive conditions.	MYC
33399078	10.1016/j.esmoop.2020.100012	2021	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.	MYC
33400146	10.1007/s11684-020-0821-6	2021	Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.	MYC
33409483	10.1016/j.metop.2020.100075	2021	Oxidative stress-mediated induction of pulmonary oncogenes, inflammatory, and apoptotic markers following time-course exposure to ethylene glycol monomethyl ether in rats.	MYC
33411331	10.15252/embj.2020105784	2021	ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.	MYC
33416496	10.7554/eLife.60191	2021	MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor-1.	MYC
33418509	10.1016/j.ebiom.2020.103191	2021	Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling.	MYC
33419818	10.21873/anticanres.14770	2021	Activation-Induced Cytidine Deaminase Promotes Proliferation and Enhances Chemoresistance and Migration in B-cell Lymphoma.	MYC
33430343	10.3390/cancers13020181	2021	Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent.	MYC
33441389	10.1136/jitc-2020-001660	2021	Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence.	MYC
33444684	10.1016/j.gene.2021.145421	2021	Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines.	MYC
33446671	10.1038/s41598-020-78947-2	2021	A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation.	MYC
33448716	10.1097/MPH.0000000000002051	2021	Precursor B-Cell Acute Lymphoblastic Leukemia With MYC and BCL2 Rearrangements Presenting as Extensive Extranodal Disease in an Adolescent.	MYC
33450085	10.1111/his.14336	2021	MYC status in HIV-associated plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry.	MYC
33480087	10.1002/hon.2839	2021	High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.	MYC
33480830	10.1080/10428194.2020.1869965	2021	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.	MYC
33494394	10.3390/cancers13030396	2021	Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma.	MYC
33509883	10.1136/bcr-2020-239014	2021	Extranodal blastoid/pleomorphic variant of mantle cell lymphoma involving the testis and skin.	MYC
33512431	10.1182/blood.2020007452	2021	Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.	MYC
33514657	10.1158/1541-7786.MCR-20-0738	2021	Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.	MYC
33521119	10.12998/wjcc.v9.i2.482	2021	Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report.	MYC
33524501	10.1016/j.canlet.2021.01.022	2021	Interleukin-10 counteracts T-helper type 1 responses in B-cell lymphoma and is a target for tumor immunotherapy.	MYC
33528622	10.1007/s00428-021-03022-8	2021	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.	MYC
33530253	10.1097/MD.0000000000024449	2021	Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.	MYC
33537096	10.7150/thno.53561	2021	Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.	MYC
33538798	10.1182/blood.2020005734	2021	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.	MYC
33548250	10.1016/j.humpath.2021.01.006	2021	Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.	MYC
33551436	10.3960/jslrt.20043	2021	DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.	MYC
33562682	10.3390/cancers13040639	2021	NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy.	MYC
33566253	10.1007/s10637-021-01079-5	2021	Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.	MYC
33572152	10.3390/cancers13040694	2021	Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma.	MYC
33591648	10.1002/brb3.2061	2021	New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).	MYC
33610538	10.1016/j.oooo.2020.11.005	2021	Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases.	MYC
33615197	10.1016/j.isci.2021.102089	2021	Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways.	MYC
33619116	10.1158/0008-5472.CAN-20-2297	2021	NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.	MYC
33619557	10.1182/blood.2020009564	2021	EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.	MYC
33636392	10.1016/j.jmoldx.2021.02.005	2021	Validation of the Double-Hit Gene Expression Signature (DLBCL90) in an Independent Cohort of Patients with Diffuse Large B-Cell Lymphoma of Germinal Center Origin.	MYC
33637566	10.1158/0008-5472.CAN-20-3351	2021	Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.	MYC
33651821	10.1371/journal.pone.0247394	2021	IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3.	MYC
33654205	10.1038/s41375-021-01181-w	2021	BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.	MYC
33655392	10.1007/s00428-021-03050-4	2021	The ""Burkitt-like"" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.	MYC
33657257	10.1111/pin.13085	2021	Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.	MYC
33660007	10.1007/s00432-021-03580-z	2021	Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.	MYC
33661537	10.1002/ajh.26151	2021	2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.	MYC
33664809	10.3892/ol.2021.12506	2021	Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma.	MYC
33668434	10.3390/molecules26040987	2021	Anti-Cancer Properties of Theaflavins.	MYC
33670870	10.3390/cancers13051002	2021	Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.	MYC
33672644	10.3390/cancers13040887	2021	Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements.	MYC
33683983	10.1177/1093526621999022	2021	EBV-Positive Plasmacytomas Involving a Nasopharyngeal Angiofibroma in an Adolescent.	MYC
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	MYC
33689920	10.1016/j.leukres.2021.106552	2021	Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.	MYC
33692924	10.7759/cureus.13155	2021	Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation.	MYC
33717748	10.7759/cureus.13209	2021	CD30-Positive Anaplastic Variant of Diffuse Large B-cell Lymphoma: Frequency and Association With Clinicopathological Parameters.	MYC
33728138	10.7759/cureus.13120	2021	Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma.	MYC
33732356	10.3892/ol.2021.12541	2021	Triptolide inhibits human telomerase reverse transcriptase by downregulating translation factors SP1 and c-Myc in Epstein-Barr virus-positive B lymphocytes.	MYC
33754004	10.7150/jca.52958	2021	R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with <i>MYC</i> rearrangement or double expression of <i>MYC</i> and <i>BCL-2</i>.	MYC
33763601	10.1515/med-2021-0246	2021	Burkitt-like lymphoma with 11q aberration in a patient with AIDS and a patient without AIDS: Two cases reports and literature review.	MYC
33768318	10.1007/s00428-021-03084-8	2021	High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.	MYC
33771538	10.1016/j.humpath.2021.03.006	2021	MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.	MYC
33774953		2021	Frequency Of Double Expressor Lymphoma In A Tertiary Care Hospital.	MYC
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	MYC
33777762	10.3389/fonc.2021.618908	2021	CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With <i>MYC</i> and <i>BCL2</i> Rearrangements.	MYC
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	MYC
33786583	10.1182/blood.2020010187	2021	Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.	MYC
33799592	10.3390/ijms22062841	2021	Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.	MYC
33801599	10.3390/ijms22073458	2021	Gene Transactivation and Transrepression in MYC-Driven Cancers.	MYC
33807449	10.3390/cancers13071620	2021	High-Grade B-Cell Lymphoma (HGBL) with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan.	MYC
33809641	10.3390/cancers13061340	2021	Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.	MYC
33811533	10.1007/s00428-021-03091-9	2021	Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas.	MYC
33812418	10.19746/j.cnki.issn.1009-2137.2021.02.027	2021	[Effects of Emodin Derivative on Cell Cycle, Apoptosis and NF-κB Pathway in Burkitt Lymphoma Cells].	MYC
33812419	10.19746/j.cnki.issn.1009-2137.2021.02.028	2021	[Up-Regulation of Bax/BCL-2 Ratio by 2-Methoxyestradiol Induces Apoptosis in Lymphoma Raji Cells].	MYC
33816589	10.3389/fvets.2021.647009	2021	Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma.	MYC
33827367	10.1080/10428194.2021.1907375	2021	Is acute lymphoblastic leukemia with mature B-cell phenotype and <i>KMT2A</i> rearrangements a new entity? A systematic review and meta-analysis.	MYC
33852185	10.1002/ardp.202000450	2021	Design, synthesis, and antiproliferative effect of 2,9-bis[4-(pyridinylalkylaminomethyl)phenyl]-1,10-phenanthroline derivatives on human leukemic cells by targeting G-quadruplex.	MYC
33858042	10.3760/cma.j.issn.0253-2727.2021.02.006	2021	[The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].	MYC
33863812	10.1158/1541-7786.MCR-20-0791	2021	CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors.	MYC
33870741	10.1177/00220345211007855	2021	Role of Mechanotransduction in Periodontal Homeostasis and Disease.	MYC
33879463	10.1136/bcr-2020-240925	2021	Early-stage Burkitt lymphoma remained in remission 7 years from diagnosis after only one cycle of chemoimmunotherapy.	MYC
33884195	10.3892/br.2021.1428	2021	Regulation of gene transcription of B lymphoma Mo-MLV insertion region 1 homolog (Review).	MYC
33893987	10.1007/s12185-021-03145-3	2021	Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.	MYC
33894159	10.1016/j.ab.2021.114206	2021	Uncovering metabolic reservoir cycles in MYC-transformed lymphoma B cells using stable isotope resolved metabolomics.	MYC
33895809	10.1182/blood.2020010144	2021	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.	MYC
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	MYC
33900450	10.1007/s00277-021-04535-7	2021	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.	MYC
33904352	10.1080/10428194.2021.1919663	2021	Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, <i>TP53</i> deletion, and <i>TP53</i> mutations.	MYC
33912162	10.3389/fimmu.2021.634584	2021	The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies.	MYC
33921029	10.3390/cancers13081907	2021	Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges.	MYC
33930347	10.1016/j.bcp.2021.114576	2021	Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.	MYC
33942298	10.1111/bjh.17255	2021	A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma.	MYC
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	MYC
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	MYC
33980611	10.1158/1541-7786.MCR-21-0267	2021	EGR1 Addiction in Diffuse Large B-cell Lymphoma.	MYC
33982372	10.1002/gcc.22971	2021	Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias.	MYC
33988072	10.1080/10428194.2021.1927020	2021	Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with <i>MYC</i> and <i>MYC</i>/<i>BCL2</i> rearrangements, especially in germinal center cell-type tumors.	MYC
33994432	10.3960/jslrt.21001	2021	Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2<sup>V617F</sup>-myeloproliferative neoplasm.	MYC
34007370	10.14740/jh818	2021	<i>MYC</i>-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge.	MYC
34017010	10.1038/s41597-021-00915-w	2021	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set.	MYC
34019298	10.1007/978-1-0716-1476-1_16	2021	Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.	MYC
34051685	10.1016/j.ejrad.2021.109784	2021	Differentiation between primary CNS lymphoma and atypical glioblastoma according to major genomic alterations using diffusion and susceptibility-weighted MR imaging.	MYC
34058070	10.1002/1878-0261.13033	2021	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.	MYC
34059753	10.1038/s41598-021-90596-7	2021	Association of killer cell immunoglobulin-like receptors with endemic Burkitt lymphoma in Kenyan children.	MYC
34078046	10.3760/cma.j.cn112151-20201223-00953	2021	[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].	MYC
34078047	10.3760/cma.j.cn112151-20210204-00127	2021	[Clinicopathological and molecular genetic features of Burkitt-like lymphoma with 11q aberration].	MYC
34078654	10.1136/jitc-2020-002029	2021	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	MYC
34079590	10.3892/ol.2021.12792	2021	MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression.	MYC
34088288	10.1186/s12906-021-03315-0	2021	Matrine suppresses cell growth of diffuse large B-cell lymphoma via inhibiting CaMKIIγ/c-Myc/CDK6 signaling pathway.	MYC
34091974	10.1111/jop.13209	2021	Burkitt lymphoma of the head and neck: An international collaborative study.	MYC
34097157	10.1007/s11864-021-00857-w	2021	Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.	MYC
34099699	10.1038/s41467-021-23695-8	2021	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.	MYC
34101913	10.1111/jop.13208	2021	Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.	MYC
34105464	10.19746/j.cnki.issn.1009-2137.2021.03.012	2021	[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].	MYC
34105893	10.1002/cam4.4062	2021	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.	MYC
34113336	10.3389/fimmu.2021.599493	2021	<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.	MYC
34114734	10.1111/jcmm.16554	2021	Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma.	MYC
34115544	10.1200/JCO.21.00086	2021	Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).	MYC
34123811	10.3389/fonc.2021.656219	2021	Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma.	MYC
34137847	10.1182/blood.2020010620	2021	Blocking RiBi to suppress MYC lymphomagenesis.	MYC
34151703	10.1080/10428194.2021.1941929	2021	Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management.	MYC
34155628	10.1111/bjh.17550	2021	Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.	MYC
34162911	10.1038/s41598-021-92448-w	2021	Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.	MYC
34165048	10.1080/10428194.2021.1907374	2021	Molecular characterization of Burkitt lymphoma in the breast or ovary.	MYC
34171161	10.1111/pin.13131	2021	Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma.	MYC
34176698	10.1053/j.semdp.2021.06.005	2021	NUT carcinoma of the lung.	MYC
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	MYC
34221962	10.3389/fonc.2021.638154	2021	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	MYC
34223928	10.1007/s00109-021-02101-2	2021	CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.	MYC
34229208	10.1016/j.tranon.2021.101170	2021	Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma.	MYC
34232987	10.1182/blood.2021011079	2021	CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival.	MYC
34252226	10.1111/cas.15061	2021	Bromodomain-containing protein 4 inhibitor JQ1 promotes melanoma cell apoptosis by regulating mitochondrial dynamics.	MYC
34255748	10.1172/JCI143119	2021	Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia.	MYC
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	MYC
34263697	10.1080/10428194.2021.1948030	2021	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).	MYC
34266887	10.1101/gad.348319.121	2021	Transient genomic instability drives tumorigenesis through accelerated clonal evolution.	MYC
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	MYC
34277639	10.3389/fcell.2021.693706	2021	HIV-1 Transactivator of Transcription (Tat) Co-operates With AP-1 Factors to Enhance <i>c-MYC</i> Transcription.	MYC
34280172	10.1097/CCO.0000000000000765	2021	Targeting SUMOylation in cancer.	MYC
34280258	10.1182/blood.2021011787	2021	BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.	MYC
34280359	10.1016/j.abb.2021.108998	2021	GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway.	MYC
34282799	10.3390/cancers13133369	2021	The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.	MYC
34283887	10.1182/blood.2021011711	2021	Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.	MYC
34284686	10.1080/10428194.2021.1953010	2021	CD5+ diffuse large B-cell lymphoma: a narrative review.	MYC
34287231	10.3390/cimb43020041	2021	Identification and Characterization of Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma Using the SORE6 Reporter.	MYC
34297745	10.1371/journal.ppat.1009764	2021	Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination.	MYC
34299194	10.3390/ijms22147576	2021	Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.	MYC
34303663	10.1016/j.ejphar.2021.174373	2021	The antipsychotic drug pimozide is effective against human T-cell leukemia virus type 1-infected T cells.	MYC
34307232	10.4322/acr.2021.278	2021	De novo double-hit B-cell precursor leukemia/lymphoma - an unusual presentation as peritoneal lymphomatosis.	MYC
34318932	10.1111/bjh.17734	2021	MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.	MYC
34330316	10.1186/s13023-021-01972-5	2021	Mature B cell acute lymphoblastic leukaemia with KMT2A-MLLT3 transcripts in children: three case reports and literature reviews.	MYC
34333327	10.1016/j.phymed.2021.153674	2021	Physciosporin suppresses mitochondrial respiration, aerobic glycolysis, and tumorigenesis in breast cancer.	MYC
34334687	10.1097/PAS.0000000000001726	2021	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.	MYC
34339901	10.1016/j.clineuro.2021.106838	2021	MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis.	MYC
34341990	10.1111/bjh.17730	2021	Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.	MYC
34347909	10.1002/hon.2902	2021	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis.	MYC
34354779	10.1016/j.jccase.2020.12.010	2021	Complete remission from post-heart transplant lymphoproliferative disorder: A case report.	MYC
34362497	10.19746/j.cnki.issn.1009-2137.2021.04.022	2021	[Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation for Patients with Diffuse Large B-Cell Lymphoma].	MYC
34362532	10.19746/j.cnki.issn.1009-2137.2021.04.057	2021	[Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].	MYC
34363012	10.1038/s41375-021-01376-1	2021	CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.	MYC
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	MYC
34380369	10.1080/10428194.2021.1964021	2021	Whole genome sequencing demonstrates substantial pathophysiological differences of <i>MYC</i> rearrangements in patients with plasma cell myeloma and B-cell lymphoma.	MYC
34384155	10.3760/cma.j.issn.0253-2727.2021.06.008	2021	[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].	MYC
34388250	10.1093/jnen/nlab080	2021	Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.	MYC
34396983	10.1172/JCI151295	2021	All in for nuclear PFKP-induced CXCR4 metastasis: a T cell acute lymphoblastic leukemia prognostic marker.	MYC
34399819	10.1186/s40170-021-00263-8	2021	Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.	MYC
34404436	10.1186/s13027-021-00396-x	2021	Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.	MYC
34405615	10.3760/cma.j.cn112151-20201207-00908	2021	[Translocations of MYC, bcl-2 and bcl-6 genes and Epstein-Barr virus infection in primary cardiac large B-cell lymphoma].	MYC
34407842	10.1186/s13046-021-02071-w	2021	SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.	MYC
34412631	10.1186/s12935-021-02143-z	2021	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.	MYC
34419613	10.1016/j.micpath.2021.105153	2021	Identification of joint gene players implicated in the pathogenesis of HTLV-1 and BLV through a comprehensive system biology analysis.	MYC
34424958	10.1182/blood.2021012052	2021	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.	MYC
34430143	10.7759/cureus.16534	2021	Clinicopathological and Immunohistochemical Profile of Mantle Cell Lymphoma: An Institutional Experience.	MYC
34437837	10.1016/j.molcel.2021.07.041	2021	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.	MYC
34438040	10.1016/j.annonc.2021.08.1991	2021	SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.	MYC
34440920	10.3390/cells10082151	2021	Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells.	MYC
34455369	10.1016/j.bbrc.2021.08.051	2021	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.	MYC
34456919	10.3389/fimmu.2021.710711	2021	Mouse Models of Germinal Center Derived B-Cell Lymphomas.	MYC
34465776	10.1038/s41467-021-25405-w	2021	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.	MYC
34477080		2021	Indurated Plaques on the Legs: Think Lymphoma.	MYC
34479963	10.1158/0008-5472.CAN-21-2734	2021	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.	MYC
34500469	10.1182/bloodadvances.2021004635	2021	Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.	MYC
34511544	10.3960/jslrt.20025	2021	Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders.	MYC
34521752	10.1073/pnas.2105440118	2021	DNA damage-induced phosphorylation of CtIP at a conserved ATM/ATR site T855 promotes lymphomagenesis in mice.	MYC
34528238	10.1111/bjh.17729	2021	Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.	MYC
34534532	10.1016/j.ejphar.2021.174505	2021	7-[[(4-methyl-2-pyridinyl)amino](2-pyridinyl)methyl]-8-quinolinol (compound 30666) inhibits enhancer activity and reduces B-cell lymphoma growth - A question of specificity.	MYC
34535769	10.1038/s41388-021-02012-z	2021	Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.	MYC
34551904	10.1158/1078-0432.CCR-21-1067	2021	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.	MYC
34557659	10.1016/j.isci.2021.102931	2021	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	MYC
34559254	10.1007/s00018-021-03940-5	2021	Assessing eukaryotic initiation factor 4F subunit essentiality by CRISPR-induced gene ablation in the mouse.	MYC
34572031	10.3390/cells10092382	2021	The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity.	MYC
34581757	10.1182/bloodadvances.2021004619	2021	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.	MYC
34584457	10.2147/CMAR.S317319	2021	Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.	MYC
34588837	10.2147/BLCTT.S330008	2021	Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission.	MYC
34588860	10.1016/j.sjbs.2021.08.020	2021	Characterization and phytochemical constituents of Periploca hydaspidis Falc crude extract and its anticancer activities.	MYC
34601505	10.1038/s41388-021-02031-w	2021	USP29 coordinates MYC and HIF1α stabilization to promote tumor metabolism and progression.	MYC
34603598	10.1155/2021/5529518	2021	One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence.	MYC
34624215	10.1016/j.molcel.2021.09.009	2021	Sex, life, and death in MYC-driven lymphomagenesis.	MYC
34625423	10.1158/0008-5472.CAN-21-1023	2021	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.	MYC
34625792	10.1182/bloodadvances.2021005682	2021	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.	MYC
34627430	10.19746/j.cnki.issn.1009-2137.2021.05.019	2021	[Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt Lymphoma].	MYC
34630126	10.3389/fphar.2021.759267	2021	LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis.	MYC
34638508	10.3390/cancers13195024	2021	RAS Mediates BET Inhibitor-Endued Repression of Lymphoma Migration and Prognosticates a Novel Proteomics-Based Subgroup of DLBCL through Its Negative Regulator IQGAP3.	MYC
34638774	10.3390/ijms221910433	2021	Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.	MYC
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	MYC
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	MYC
34679437	10.3390/diagnostics11101739	2021	Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.	MYC
34680290	10.3390/cancers13205141	2021	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.	MYC
34698437	10.1111/jcmm.16999	2021	Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.	MYC
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	MYC
34707037	10.3960/jslrt.21025	2021	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma.	MYC
34732441	10.21873/anticanres.15384	2021	Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.	MYC
34742294	10.1186/s13000-021-01163-7	2021	Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.	MYC
34748616	10.1371/journal.ppat.1010045	2021	ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells.	MYC
34757246	10.1016/j.cancergen.2021.10.006	2021	A new dual translocation of chromosome 14 in a pediatric Burkitt lymphoma/leukemia patient: t(8;14) and t(14;15).	MYC
34763718	10.1186/s13046-021-02159-3	2021	ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.	MYC
34782660	10.1038/s41598-021-01693-6	2021	Primary central nervous system lymphomas express immunohistochemical factors of autophagy.	MYC
34785569	10.1136/lupus-2021-000561	2021	Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases.	MYC
34804437	10.4084/MJHID.2021.063	2021	Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL.	MYC
34804942	10.3389/fonc.2021.754180	2021	Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China.	MYC
34806851	10.20892/j.issn.2095-3941.2021.0193	2021	Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.	MYC
34819491	10.1038/s41408-021-00578-1	2021	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma.	MYC
34821060	10.1002/cam4.4394	2021	Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo.	MYC
34821091	10.12047/j.cjap.6159.2021.095	2021	[Effects of miR-155-3p on the degradation rate of EAF1 mRNA and malignant proliferation in HANK1 cells].	MYC
34830747	10.3390/cancers13225592	2021	Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.	MYC
34837933	10.31557/APJCP.2021.22.11.3723	2021	Investigation the Cytotoxicity of 5-AZA on Acute Lymphoblastic Leukemia Cell Line In Vitro and Characterization the Underlying Molecular Mechanisms of Cell Death and Motility.	MYC
34857874	10.1038/s42003-021-02853-0	2021	KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth.	MYC
34858727	10.1080/2162402X.2021.2003533	2021	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.	MYC
34868769	10.7759/cureus.19130	2021	Adult Nodal Burkitt Lymphoma Forming Nodular Architectures.	MYC
34885010	10.3390/cancers13235900	2021	CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL.	MYC
34885204	10.3390/cancers13236093	2021	Differential Transcriptional Reprogramming by Wild Type and Lymphoma-Associated Mutant MYC Proteins as B-Cells Convert to a Lymphoma Phenotype.	MYC
34888589	10.21037/aol-21-18	2021	Reframing Burkitt lymphoma: virology not epidemiology defines clinical variants.	MYC
34889402	10.1182/hematology.2021000247	2021	Double-hit lymphoma: optimizing therapy.	MYC
34893113	10.19746/j.cnki.issn.1009-2137.2021.06.018	2021	[The Effect of Bcl-6 Expression on the Prognosis of Newly Treated Double-Expressing Lymphoma Treated with R-CHOP Regimen].	MYC
34898570	10.3390/curroncol28060393	2021	Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients.	MYC
34907175	10.1038/s41467-021-27197-5	2021	Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.	MYC
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	MYC
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	MYC
34956871	10.3389/fonc.2021.746577	2021	Clinical Features and Prognostic Significance of <i>NOTCH1</i> Mutations in Diffuse Large B-Cell Lymphoma.	MYC
34967583	10.31557/APJCP.2021.22.12.4011	2021	Association between c-Myc Expression with Clinicopathological Features in T And NK Cell Lymphomas.	MYC
35004320	10.3389/fonc.2021.795330	2021	Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With <i>MYC</i> and <i>BCL6</i> Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?	MYC
35008547	10.3390/ijms23010122	2021	Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform.	MYC
35045655	10.3760/cma.j.issn.0253-2727.2021.11.008	2021	[Effects of L-asparaginase on proliferation, cell cycle and apoptosis of Burkitt lymphoma cell lines].	MYC
35116484	10.21037/tcr-20-2748	2021	""Double hit"" B-lymphoblastic lymphoma with concurrent <i>IGH</i>/<i>BCL2</i> and 8q24/<i>MYC</i> translocations: a case report.	MYC
35432798	10.22038/IJBMS.2021.58633.13025	2021	Combination of auraptene and arsenic trioxide induces apoptosis and cellular accumulation in the subG1 phase in adult T-cell leukemia cells.	MYC
35582389	10.20517/cdr.2021.55	2021	MYC inhibitors in multiple myeloma.	MYC
31348551	10.1111/his.13959	2020	High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma.	MYC
31399522	10.3324/haematol.2019.223891	2020	An increase in <i>MYC</i> copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.	MYC
31462708	10.1038/s41388-019-0973-5	2020	ALK<sup>ATI</sup> interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma.	MYC
31706988	10.1016/j.yexmp.2019.104326	2020	CD5<sup>+</sup>MYC<sup>+</sup> predicts worse prognosis in diffuse large B-cell lymphoma.	MYC
31776900	10.1007/s11060-019-03348-z	2020	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.	MYC
31844144	10.1038/s41375-019-0691-6	2020	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.	MYC
31932576	10.1038/s41408-019-0271-z	2020	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?	MYC
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	MYC
32011831	10.17219/acem/112608	2020	Analysis of the rRNA methylation complex components in pediatric B-cell precursor acute lymphoblastic leukemia: A pilot study.	MYC
32074595	10.1159/000505892	2020	The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.	MYC
32101329	10.1002/hon.2727	2020	Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.	MYC
32101699	10.1016/j.chembiol.2020.02.002	2020	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome.	MYC
32334477	10.31557/APJCP.2020.21.4.1103	2020	The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.	MYC
32350066	10.1158/0008-5472.CAN-19-2247	2020	FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.	MYC
32373977	10.26355/eurrev_202004_21021	2020	Association between C-myc and K-ras gene polymorphisms and non-Hodgkin lymphoma.	MYC
32391636	10.1111/jcmm.15322	2020	Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.	MYC
32420596	10.1042/CS20200032	2020	Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis.	MYC
32432756	10.26355/eurrev_202005_21182	2020	GPAA1 promotes progression of childhood acute lymphoblastic leukemia through regulating c-myc.	MYC
32497402	10.1002/cyto.b.21887	2020	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.	MYC
32503978	10.1038/s41467-020-16447-7	2020	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.	MYC
32549409	10.3390/ijms21124265	2020	Insights about MYC and Apoptosis in B-Lymphomagenesis: An Update from Murine Models.	MYC
32566654	10.1155/2020/1350820	2020	Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study.	MYC
32632092	10.1038/s41392-020-00236-1	2020	YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma.	MYC
32659596	10.1016/j.molimm.2020.06.029	2020	The c-Rel-c-Myc axis controls metabolism and proliferation of human T leukemia cells.	MYC
32722781	10.1182/bloodadvances.2020001551	2020	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.	MYC
32728938	10.1007/s00277-020-04200-5	2020	The prognostic value of 25-hydroxy vitamin D deficiency and its interaction with c-Myc expression in diffuse large B cell lymphoma.	MYC
32833271	10.1002/ajh.25980	2020	""Double hit"" anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements.	MYC
32889391	10.1016/j.anndiagpath.2020.151610	2020	Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.	MYC
32921221	10.1080/10428194.2020.1815017	2020	Clinicopathological and prognostic significance of <i>BCL2</i>, <i>BCL6</i>, <i>MYC</i>, and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis.	MYC
32981916	10.3960/jslrt.20021	2020	Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.	MYC
32991338	10.1097/PAS.0000000000001577	2020	High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.	MYC
33168821	10.1038/s41408-020-00382-3	2020	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.	MYC
33298911	10.1038/s41467-020-20107-1	2020	TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.	MYC
33298918	10.1038/s41467-020-20136-w	2020	Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.	MYC
33300052	10.3892/ijo.2020.5128	2020	lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‑495‑3p/MYCBP axis.	MYC
33333886	10.3390/cells9122692	2020	Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.	MYC
33335784	10.1155/2020/8876567	2020	Clonally Related Plasmablastic Lymphoma Simultaneously Occurring with Diffuse Large B-Cell Lymphoma.	MYC
33339535	10.1186/s13256-020-02526-2	2020	Double-hit lymphoma of the male breast: a case report.	MYC
33344238	10.3389/fonc.2020.584095	2020	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas.	MYC
33365186	10.25259/SNI_314_2020	2020	Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.	MYC
33489398	10.1155/2020/8875547	2020	Plasmablastic Lymphoma Associated with Adjacent Mature Plasma Cell Population Exhibiting Opposite Light Chain Restriction.	MYC
29741984	10.1080/10428194.2018.1464158	2019	MYC protein expression is an important prognostic factor in acute myeloid leukemia.	MYC
29954940	10.3324/haematol.2018.195958	2019	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.	MYC
29974930	10.1111/bjh.15431	2019	Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement.	MYC
30306208	10.1007/s00277-018-3498-z	2019	MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.	MYC
30460680	10.1111/bjh.15653	2019	Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	MYC
30737994	10.1111/ejh.13219	2019	Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome.	MYC
30739786	10.1016/j.bbrc.2019.01.105	2019	LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.	MYC
30825244	10.1002/jcb.28529	2019	c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma.	MYC
30912195	10.1111/iep.12307	2019	Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.	MYC
30953469	10.1186/s12885-019-5537-0	2019	Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.	MYC
31127282	10.1093/nar/gkz462	2019	Acute depletion of CTCF directly affects MYC regulation through loss of enhancer-promoter looping.	MYC
31127909	10.31557/APJCP.2019.20.5.1463	2019	C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma	MYC
31138843	10.1038/s41375-019-0492-y	2019	Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.	MYC
31142587	10.1084/jem.20181726	2019	c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma.	MYC
31173259	10.3892/or.2019.7183	2019	miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.	MYC
31257571	10.1111/bjh.16082	2019	Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement.	MYC
31259656	10.1080/10428194.2019.1633629	2019	The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.	MYC
31266538	10.1186/s13072-019-0278-5	2019	MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.	MYC
31266772	10.1158/0008-5472.CAN-18-2847	2019	<i>MYC</i> Regulates the <i>HIF2α</i> Stemness Pathway via <i>Nanog</i> and <i>Sox2</i> to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells.	MYC
31315646	10.1186/s13000-019-0856-7	2019	Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.	MYC
31498031	10.1200/JCO.19.00743	2019	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.	MYC
31767764	10.1073/pnas.1910391116	2019	Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance.	MYC
28838257	10.1080/10428194.2017.1365851	2018	Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.	MYC
28868942	10.1080/10428194.2017.1370547	2018	MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.	MYC
29112016	10.1097/PAS.0000000000000982	2018	B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients.	MYC
29118124	10.1128/JVI.01178-17	2018	c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.	MYC
29180471	10.1158/0008-5472.CAN-17-0815	2018	MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.	MYC
29229300	10.1016/j.bbagen.2017.12.002	2018	c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.	MYC
29284789	10.1038/s41388-017-0055-5	2018	Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis.	MYC
29289266	10.1016/j.amjms.2017.06.007	2018	Is Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer.	MYC
29314290	10.1002/mc.22781	2018	Oncogene RNA helicase DDX6 promotes the process of c-Myc expression in gastric cancer cells.	MYC
29367285	10.15252/embr.201744871	2018	Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia.	MYC
29666061	10.1158/0008-5472.CAN-17-3107	2018	Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.	MYC
29666157	10.1136/jclinpath-2018-205039	2018	CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.	MYC
29708579	10.5146/tjpath.2018.01430	2018	Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma.	MYC
29749488	10.3892/mmr.2018.8935	2018	C‑Myc inhibitor 10058‑F4 increases the efficacy of dexamethasone on acute lymphoblastic leukaemia cells.	MYC
29801406	10.22034/APJCP.2018.19.5.1229	2018	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience	MYC
29885057	10.1002/path.5110	2018	Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.	MYC
30015962	10.3892/or.2018.6581	2018	Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancer.	MYC
30043475	10.1002/dc.24038	2018	""Triple hit"" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.	MYC
30099568	10.1007/s00277-018-3439-x	2018	Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and induces apoptosis of diffuse large B cell lymphoma cells.	MYC
30113335	10.1097/PAS.0000000000001132	2018	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.	MYC
30115641	10.1182/bloodadvances.2018016048	2018	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.	MYC
30237309	10.15252/embj.201798589	2018	Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.	MYC
30260324	10.1172/JCI122533	2018	PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.	MYC
30282799	10.1182/blood-2018-03-842088	2018	IG-<i>MYC</i> <sup>+</sup> neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.	MYC
27687004	10.1038/modpathol.2016.162	2017	Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.	MYC
27687005	10.1038/modpathol.2016.56	2017	Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.	MYC
27729620	10.18632/oncotarget.12535	2017	The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis.	MYC
27776009	10.1097/PAS.0000000000000758	2017	Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.	MYC
27987331	10.1002/jcb.25845	2017	IRS1/β-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells.	MYC
27993575	10.1016/j.humpath.2016.12.007	2017	B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry.	MYC
28055963	10.18632/oncotarget.14393	2017	Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.	MYC
28119527	10.1038/leu.2017.40	2017	RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.	MYC
28212447	10.1371/journal.pone.0172364	2017	Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.	MYC
28232371	10.3324/haematol.2016.156281	2017	c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells.	MYC
28280048	10.1182/blood-2016-10-745620	2017	A CD34-negative <i>MYC</i>-rearranged B-lymphoblastic lymphoma aberrantly expresses CD3 and CD5.	MYC
28291124	10.1097/PAS.0000000000000799	2017	MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.	MYC
28327893	10.1093/annonc/mdx022	2017	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.	MYC
28344317	10.1038/leu.2017.99	2017	Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.	MYC
28344319	10.1038/leu.2017.103	2017	PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.	MYC
28351934	10.1182/blood-2016-11-747022	2017	Genetic profiling of <i>MYC</i> and <i>BCL2</i> in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.	MYC
28368423	10.1038/onc.2017.95	2017	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.	MYC
28498285	10.1097/PAS.0000000000000871	2017	C-MYC and Its Main Ubiquitin Ligase, FBXW7, Influence Cell Proliferation and Prognosis in Adult T-cell Leukemia/Lymphoma.	MYC
28498893	10.1093/carcin/bgx041	2017	Role of DHX33 in c-Myc-induced cancers.	MYC
28521631	10.1177/1093526616689642	2017	Immunohistochemical Profile of MYC Protein in Pediatric Small Round Blue Cell Tumors.	MYC
28614202	10.1097/PAS.0000000000000818	2017	Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology.	MYC
28639315	10.1111/his.13287	2017	MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.	MYC
28665415	10.1038/bcj.2017.59	2017	Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas.	MYC
28686226	10.1038/bcj.2017.61	2017	MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.	MYC
28776574	10.1038/modpathol.2017.93	2017	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.	MYC
28790107	10.1182/blood-2017-03-775536	2017	RUNX1 is required for oncogenic <i>Myb</i> and <i>Myc</i> enhancer activity in T-cell acute lymphoblastic leukemia.	MYC
28800143	10.1111/cup.13025	2017	Immunohistochemistry reveals an increased proportion of MYC-positive cells in subcutaneous panniculitis-like T-cell lymphoma compared with lupus panniculitis.	MYC
28914785	10.3390/ijms18091986	2017	Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.	MYC
28952038	10.1007/s11912-017-0629-y	2017	Double-Hit Large B Cell Lymphoma.	MYC
29044419	10.1093/jnen/nlx083	2017	MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.	MYC
29088292	10.1371/journal.pone.0186983	2017	Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.	MYC
29198442	10.1016/j.trecan.2017.09.008	2017	Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma.	MYC
29209623	10.1155/2017/1967648	2017	<i>MYC</i> Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection.	MYC
25982280	10.1038/onc.2015.167	2016	Scribble acts as an oncogene in Eμ-myc-driven lymphoma.	MYC
26119939	10.1038/onc.2015.245	2016	Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.	MYC
26307073	10.1136/jclinpath-2015-203002	2016	Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.	MYC
26340843	10.1111/ejh.12680	2016	CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.	MYC
26390147	10.3109/10428194.2015.1096352	2016	Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.	MYC
26421520	10.3109/10428194.2015.1101099	2016	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.	MYC
26448193	10.1097/PAS.0000000000000542	2016	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.	MYC
26565895	10.1002/cncr.29781	2016	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.	MYC
26568397	10.1111/bjh.13844	2016	Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.	MYC
26573234	10.18632/oncotarget.6262	2016	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.	MYC
26820684	10.1016/j.ejca.2015.12.001	2016	Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.	MYC
26848526	10.18632/oncotarget.7134	2016	Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.	MYC
26873538	10.1002/jcb.25516	2016	Distinct Patterns of Colocalization of the CCND1 and CMYC Genes With Their Potential Translocation Partner IGH at Successive Stages of B-Cell Differentiation.	MYC
26916070	10.1038/modpathol.2016.35	2016	The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia.	MYC
26917778	10.1182/blood-2015-02-629485	2016	4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.	MYC
26966191	10.1126/science.aac9935	2016	MYC regulates the antitumor immune response through CD47 and PD-L1.	MYC
26988986	10.1158/0008-5472.CAN-15-2477	2016	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.	MYC
27071312	10.3109/10428194.2016.1167205	2016	Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.	MYC
27125356	10.1038/modpathol.2016.71	2016	Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression.	MYC
27151990	10.3324/haematol.2016.143768	2016	C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas.	MYC
27239040	10.1016/j.celrep.2016.05.015	2016	PIAS1 Promotes Lymphomagenesis through MYC Upregulation.	MYC
27243588	10.1080/10428194.2016.1187275	2016	Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma.	MYC
27282353	10.1038/modpathol.2016.114	2016	Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.	MYC
27286976	10.1186/s12885-016-2397-8	2016	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.	MYC
27339797	10.1038/ncomms11807	2016	MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation.	MYC
27341130	10.18632/oncotarget.10187	2016	p63α modulates c-Myc activity via direct interaction and regulation of MM1 protein stability.	MYC
27391453	10.1097/DAD.0000000000000607	2016	Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.	MYC
27448819	10.1007/s13277-016-5225-5	2016	PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.	MYC
27469075	10.1111/bjh.14282	2016	Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.	MYC
27490482	10.7554/eLife.18270	2016	MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.	MYC
27544800	10.1016/j.humpath.2016.07.025	2016	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.	MYC
27590350	10.18632/oncotarget.11718	2016	Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.	MYC
27633159	10.1016/j.clml.2016.08.017	2016	Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma.	MYC
27635472	10.18632/oncotarget.11719	2016	The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.	MYC
27748879	10.3892/mmr.2016.5818	2016	Quercetin-induced apoptosis of HT-29 colon cancer cells via inhibition of the Akt-CSN6-Myc signaling axis.	MYC
27810071	10.1016/j.cancergen.2016.08.007	2016	MYC rearranged B-cell neoplasms: Impact of genetics on classification.	MYC
27821172	10.1186/s13045-016-0349-z	2016	A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma.	MYC
27840026	10.1016/j.molcel.2016.10.012	2016	CRY2 and FBXL3 Cooperatively Degrade c-MYC.	MYC
27886239	10.1038/srep37772	2016	Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma.	MYC
24679006	10.3109/10428194.2014.907896	2015	TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.	MYC
24731854	10.1016/j.bbagrm.2014.04.004	2015	The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.	MYC
24844357	10.3109/10428194.2014.924116	2015	Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.	MYC
24998853	10.1038/onc.2014.186	2015	A common functional consequence of tumor-derived mutations within c-MYC.	MYC
25103070	10.1038/modpathol.2014.95	2015	B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.	MYC
25219592	10.3109/10428194.2014.963575	2015	Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC.	MYC
25229766	10.1097/PAS.0000000000000319	2015	Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations.	MYC
25284491	10.3109/10428194.2014.970550	2015	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.	MYC
25311243	10.1038/leu.2014.302	2015	A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.	MYC
25359993	10.1182/blood-2014-08-594507	2015	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.	MYC
25373509	10.3109/10428194.2014.982643	2015	ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A.	MYC
25468432	10.1016/j.jmoldx.2014.08.006	2015	Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.	MYC
25487600	10.1016/j.clml.2014.10.003	2015	Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.	MYC
25531321	10.1038/onc.2014.427	2015	c-MYC is a radiosensitive locus in human breast cells.	MYC
25581730	10.1097/PAS.0000000000000365	2015	Expression profiles of MYC protein and MYC gene rearrangement in lymphomas.	MYC
25595783	10.4049/jimmunol.1402382	2015	Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.	MYC
25621564	10.7554/eLife.04024	2015	Registered report: transcriptional amplification in tumor cells with elevated c-Myc.	MYC
25673238	10.1038/leu.2015.34	2015	The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum.	MYC
25690653	10.1096/fj.14-263889	2015	Long noncoding RNAs as a novel component of the Myc transcriptional network.	MYC
25692307	10.1080/15384047.2014.1002698	2015	Inauhzin(c) inactivates c-Myc independently of p53.	MYC
25739120	10.18632/oncotarget.3245	2015	Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.	MYC
25741152	10.3748/wjg.v21.i8.2433	2015	Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.	MYC
25784651	10.18632/oncotarget.2969	2015	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.	MYC
25827211	10.3109/10428194.2015.1034699	2015	Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.	MYC
25828389	10.1097/PAS.0000000000000433	2015	MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.	MYC
25828391	10.1097/PAS.0000000000000434	2015	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.	MYC
26010683	10.1111/apm.12390	2015	MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.	MYC
26062055	10.1002/hon.2217	2015	IX. Is it only about MYC? How to approach the diagnosis of diffuse large B-cell lymphomas.	MYC
26158410	10.18632/oncotarget.4073	2015	MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.	MYC
26261666		2015	Richter transformation with c-MYC overexpression: report of three cases.	MYC
26261669		2015	Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.	MYC
26317903	10.18632/oncotarget.4620	2015	Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.	MYC
26327622	10.1371/journal.ppat.1005135	2015	KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice.	MYC
26453442	10.1186/s12885-015-1661-7	2015	Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.	MYC
26515759	10.1186/s13045-015-0218-1	2015	Establishment and characterization of a novel MYC/BCL2 ""double-hit"" diffuse large B cell lymphoma cell line, RC.	MYC
26517351	10.18632/oncotarget.5982	2015	Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia.	MYC
26517511	10.18632/oncotarget.5705	2015	High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival.	MYC
26558423	10.3109/08880018.2015.1087611	2015	De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.	MYC
26634708	10.1007/s11864-015-0374-0	2015	Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.	MYC
26717387	10.1097/MD.0000000000002388	2015	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.	MYC
23416976	10.1038/onc.2013.28	2014	Sensitisation of c-MYC-induced B-lymphoma cells to apoptosis by ATF2.	MYC
24118498	10.1111/ejh.12212	2014	MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations.	MYC
24249258	10.1002/gcc.22117	2014	MYC fails to efficiently shape malignant transformation in T-cell acute lymphoblastic leukemia.	MYC
24368766	10.1074/jbc.M113.525949	2014	SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.	MYC
24394663	10.1182/blood-2013-08-522698	2014	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.	MYC
24397618	10.3109/10428194.2013.879714	2014	Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry.	MYC
24398325	10.1182/blood-2013-06-507996	2014	A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.	MYC
24503701	10.1371/journal.pone.0087456	2014	Immunohistochemistry for myc predicts survival in colorectal cancer.	MYC
24552990	10.1038/leu.2014.78	2014	Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.	MYC
24586197	10.1371/journal.pgen.1004167	2014	Insertional mutagenesis and deep profiling reveals gene hierarchies and a Myc/p53-dependent bottleneck in lymphomagenesis.	MYC
24614102	10.1172/JCI63139	2014	CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.	MYC
24614699	10.1097/PAT.0000000000000076	2014	Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis.	MYC
24619762	10.1309/AJCPPHMZ6VHF0WQV	2014	p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.	MYC
24625415	10.1097/PAS.0000000000000147	2014	Clinical significance of MYC expression and/or ""high-grade"" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.	MYC
24642368	10.1016/j.prp.2014.02.004	2014	Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China.	MYC
24675470	10.1038/cddis.2014.112	2014	Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.	MYC
24686171	10.1158/0008-5472.CAN-13-2732	2014	Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression.	MYC
24705315	10.1097/PAS.0000000000000213	2014	MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).	MYC
24713985	10.1097/PAP.0b013e3182a92cde	2014	Burkitt lymphoma and MYC: what else is new?	MYC
24719189	10.1007/s13277-014-1907-z	2014	MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.	MYC
24740248	10.1371/journal.pone.0095020	2014	C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies.	MYC
24809777	10.1038/bjc.2014.218	2014	Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.	MYC
24913718	10.1158/2326-6066.CIR-14-0090	2014	Mechanisms that can promote peripheral B-cell lymphoma in ATM-deficient mice.	MYC
24994904	10.1073/pnas.1409778111	2014	Alteration of the lipid profile in lymphomas induced by MYC overexpression.	MYC
25034145	10.1038/leu.2014.224	2014	Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model.	MYC
25060305	10.1016/j.leukres.2014.06.022	2014	C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?	MYC
25060588	10.1002/cncr.28899	2014	MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.	MYC
25090026	10.1371/journal.pone.0104068	2014	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.	MYC
25125624	10.1309/AJCPBWVHTF7RRSA4	2014	Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.	MYC
25125625	10.1309/AJCPUBHM8U7ZFLOB	2014	Aberrations of MYC are a common event in B-cell prolymphocytic leukemia.	MYC
25194570	10.1038/nm.3665	2014	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.	MYC
25261932	10.1038/ng.3105	2014	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	MYC
25270907	10.1182/blood-2014-06-578856	2014	Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations.	MYC
25297597	10.3760/cma.j.issn.1003-9406.2014.01.020	2014	[Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].	MYC
25337204		2014	C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.	MYC
25369933	10.1073/pnas.1407079111	2014	Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.	MYC
25479599	10.1371/journal.pone.0114398	2014	MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.	MYC
26016222		2014	[Clinical features in DLBCL and translocation BCL2/c-MYC ""double hit"" lymphoma].	MYC
22484426	10.1038/onc.2012.117	2013	Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.	MYC
22957790	10.3109/10428194.2012.704034	2013	Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.	MYC
22967991	10.1093/annonc/mds209	2013	A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.	MYC
23012230	10.1002/gcc.22008	2013	Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.	MYC
23178486	10.1038/onc.2012.543	2013	STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.	MYC
23237560	10.1016/j.leukres.2012.11.010	2013	c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas.	MYC
23243310	10.1074/jbc.M112.410274	2013	Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.	MYC
23330001		2013	Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.	MYC
23335369	10.1182/blood-2012-06-435842	2013	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.	MYC
23341364	10.1002/path.4164	2013	Decitabine represses translocated MYC oncogene in Burkitt lymphoma.	MYC
23355209	10.1309/AJCP2Z0TAGMUYJEB	2013	Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma.	MYC
23363269	10.3109/10428194.2013.771398	2013	MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.	MYC
23449635	10.1182/blood-2012-10-460063	2013	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.	MYC
23525267	10.1158/1541-7786.MCR-12-0441	2013	Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.	MYC
23538750	10.1038/leu.2013.94	2013	Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.	MYC
23589839	10.1073/pnas.1208530110	2013	Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis.	MYC
23599149	10.1038/modpathol.2013.73	2013	ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.	MYC
23601184	10.1111/febs.12299	2013	Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma.	MYC
23716551	10.3324/haematol.2013.086173	2013	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.	MYC
23770605	10.1038/ng.2652	2013	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.	MYC
23791182	10.1016/j.cell.2013.05.041	2013	The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.	MYC
23795946	10.1111/his.12178	2013	MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection.	MYC
23797802	10.1097/CAD.0b013e328363ae50	2013	Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.	MYC
23821202	10.1167/iovs.13-12272	2013	MicroRNA profiling in ocular adnexal lymphoma: a role for MYC and NFKB1 mediated dysregulation of microRNA expression in aggressive disease.	MYC
23926923	10.1111/his.12207	2013	Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.	MYC
23933736	10.1093/hmg/ddt381	2013	Myc inhibition impairs autophagosome formation.	MYC
23939148	10.1097/PAP.0b013e3182a289f2	2013	MYC/BCL2 double-hit high-grade B-cell lymphoma.	MYC
23982173	10.1182/blood-2013-02-484055	2013	Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.	MYC
24009228	10.1182/blood-2013-05-498329	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	MYC
24040459		2013	Primary sacral non-germinal center type diffuse large B-cell lymphoma with MYC translocation: a case report and a review of the literature.	MYC
24140063	10.1016/j.bbrc.2013.10.034	2013	C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells.	MYC
24152439	10.3390/ijms141020236	2013	Acidosis decreases c-Myc oncogene expression in human lymphoma cells: a role for the proton-sensing G protein-coupled receptor TDAG8.	MYC
24169826	10.1182/blood-2012-12-473090	2013	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.	MYC
24216476	10.1172/JCI64210	2013	A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.	MYC
24319234	10.1182/asheducation-2013.1.575	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	MYC
20981461	10.1007/s10006-010-0254-5	2012	Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case.	MYC
21882178	10.1002/cncr.26433	2012	Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.	MYC
21913186	10.1002/ijc.26423	2012	High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas.	MYC
22002311	10.1038/onc.2011.470	2012	Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.	MYC
22002575	10.1038/modpathol.2011.147	2012	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	MYC
22081066	10.1038/onc.2011.507	2012	Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.	MYC
22120970	10.1002/gcc.21915	2012	Molecular analysis of the t(2;8)/MYC-IGK translocation in high-grade lymphoma/leukemia by long-distance inverse PCR.	MYC
22168746	10.1111/j.1349-7006.2011.02186.x	2012	Role of activation-induced cytidine deaminase in the progression of follicular lymphoma.	MYC
22314191	10.1097/PAS.0b013e318244e2ba	2012	High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.	MYC
22333947	10.1016/S0140-6736(11)61177-X	2012	Burkitt's lymphoma.	MYC
22393362	10.1371/journal.pone.0031366	2012	Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.	MYC
22453922	10.1074/jbc.M111.335216	2012	Kaposi sarcoma-associated herpesvirus vIRF-3 protein binds to F-box of Skp2 protein and acts as a regulator of c-Myc protein function and stability.	MYC
22615405	10.1073/pnas.1203244109	2012	Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.	MYC
22661084	10.4049/jimmunol.1102277	2012	B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels.	MYC
22665537	10.1200/JCO.2011.41.4342	2012	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	MYC
22804688	10.1111/j.1365-2559.2012.04301.x	2012	High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis.	MYC
22826319	10.4049/jimmunol.1201000	2012	A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.	MYC
22844532	10.1371/journal.pone.0041891	2012	Rabring7 degrades c-Myc through complex formation with MM-1.	MYC
22851565	10.1200/JCO.2011.41.0985	2012	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	MYC
22863009	10.1016/j.cell.2012.06.033	2012	Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state.	MYC
22897848	10.1016/j.ccr.2012.06.012	2012	Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.	MYC
22949148	10.1200/JCO.2012.44.4729	2012	Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.	MYC
23018644	10.1182/blood-2012-05-428466	2012	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.	MYC
23042398	10.3760/cma.j.issn.1003-9406.2012.05.017	2012	[Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].	MYC
23079660	10.1016/j.ccr.2012.09.003	2012	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.	MYC
23143306	10.1172/JCI62973	2012	ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.	MYC
23175515	10.18632/oncotarget.748	2012	Epigenetics, c-Myc and aggressive B-cell lymphomas.	MYC
20661666	10.1007/s12032-010-9614-0	2011	Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement.	MYC
21217079	10.1182/blood-2010-05-286351	2011	Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia.	MYC
21245140	10.1074/jbc.M110.165977	2011	SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.	MYC
21478429	10.1182/blood-2010-10-315432	2011	Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway.	MYC
21527520	10.1182/blood-2011-02-336842	2011	Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia.	MYC
21628855	10.3960/jslrt.51.7	2011	BCL2 and MYC dual-hit lymphoma/leukemia.	MYC
21640157	10.1016/j.exphem.2011.05.002	2011	Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.	MYC
21646687	10.18632/oncotarget.283	2011	The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.	MYC
21692100	10.1002/hon.991	2011	Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.	MYC
21783402	10.1016/j.oraloncology.2011.06.506	2011	Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas.	MYC
21878679	10.1126/scisignal.2001754	2011	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.	MYC
21949397	10.1073/pnas.1108190108	2011	Targeting MYC dependence in cancer by inhibiting BET bromodomains.	MYC
22022427	10.1371/journal.pone.0025645	2011	Notch ankyrin repeat domain variation influences leukemogenesis and Myc transactivation.	MYC
19881537	10.1038/onc.2009.377	2010	c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.	MYC
20087644	10.1007/s10552-010-9504-y	2010	Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.	MYC
20118770	10.1097/PAS.0b013e3181cd3aeb	2010	B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.	MYC
20133585	10.1073/pnas.0901230107	2010	Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model.	MYC
20378577	10.3324/haematol.2009.012864	2010	Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.	MYC
20442643	10.1097/PAS.0b013e3181db83af	2010	Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.	MYC
20498406	10.1200/JCO.2009.26.3947	2010	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.	MYC
20573831	10.1128/JVI.00244-10	2010	Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency.	MYC
20598117	10.1186/1471-2407-10-348	2010	Myc suppression of Nfkb2 accelerates lymphomagenesis.	MYC
20737197	10.1007/s11010-010-0536-0	2010	The impact of C-MYC gene expression on gastric cancer cell.	MYC
20823132	10.3324/haematol.2010.025767	2010	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.	MYC
20823134	10.3324/haematol.2010.026831	2010	Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.	MYC
20962620	10.1097/PAS.0b013e3181f3e29f	2010	IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.	MYC
19022773	10.1074/jbc.M808080200	2009	TGF-beta induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1.	MYC
19038003	10.1111/j.1349-7006.2008.01035.x	2009	Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma.	MYC
19179467	10.1182/blood-2008-10-183475	2009	Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine.	MYC
19219026	10.1038/nature07823	2009	c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.	MYC
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	MYC
19497851	10.1074/jbc.M109.021477	2009	DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.	MYC
19535347	10.3324/haematol.2008.005355	2009	Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.	MYC
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	MYC
19594747	10.1111/j.1365-2141.2009.07791.x	2009	Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.	MYC
19597184	10.1182/blood-2009-03-212191	2009	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.	MYC
19704118	10.1182/blood-2009-05-220095	2009	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.	MYC
19755676	10.1182/blood-2008-12-196709	2009	TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas.	MYC
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	MYC
19815507	10.1073/pnas.0907994106	2009	Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.	MYC
19996270	10.1158/1535-7163.MCT-09-0408	2009	Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells.	MYC
17989722	10.1038/sj.leu.2404999	2008	Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas.	MYC
18066065	10.1038/ng.2007.30	2008	Widespread microRNA repression by Myc contributes to tumorigenesis.	MYC
18085637	10.1002/cncr.23196	2008	The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.	MYC
18089500	10.1309/NKK3FEX2BE5L7EKB	2008	Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event.	MYC
18235046	10.1182/blood-2007-08-108654	2008	PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.	MYC
18297523	10.1080/10428190701836845	2008	C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator?	MYC
18393360	10.1002/jcb.21765	2008	c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.	MYC
18426731	10.1309/CMPGPYTMFRM6RVQR	2008	Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene.	MYC
18460403	10.1016/j.leukres.2007.10.006	2008	Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes.	MYC
18535662	10.1371/journal.pgen.1000090	2008	Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis.	MYC
18628958	10.1371/journal.pone.0002722	2008	Global regulation of nucleotide biosynthetic genes by c-Myc.	MYC
18713946	10.1182/blood-2008-03-147645	2008	MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.	MYC
18752503	10.1111/j.1365-2559.2008.03076.x	2008	MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.	MYC
18754028	10.1038/leu.2008.230	2008	Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).	MYC
17310999	10.1038/sj.onc.1210299	2007	Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen.	MYC
17363738	10.1182/blood-2006-08-039883	2007	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.	MYC
17419945	10.1016/S0065-230X(06)97007-9	2007	c-MYC impairs immunogenicity of human B cells.	MYC
17541401	10.1038/sj.leu.2404753	2007	Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma.	MYC
17613764	10.1080/10428190701402903	2007	Characterization of genetic changes in MCL by interphase FISH on tissue sections.	MYC
17622571	10.1182/blood-2006-09-048033	2007	Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.	MYC
17634226	10.1128/JVI.00804-07	2007	The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc.	MYC
17646408	10.1084/jem.20070872	2007	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	MYC
17728244	10.1074/jbc.M706430200	2007	Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus.	MYC
17785433	10.1128/MCB.00440-07	2007	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.	MYC
18024371	10.3324/haematol.11305	2007	The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.	MYC
16432227	10.1073/pnas.0507367103	2006	ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.	MYC
16466700	10.1016/j.bbrc.2006.01.097	2006	c-Myc over-expression in Ramos Burkitt's lymphoma cell line predisposes to iron homeostasis disruption in vitro.	MYC
16508012	10.1128/MCB.26.6.2373-2386.2006	2006	Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.	MYC
16537801	10.1182/blood-2006-01-0172	2006	MYC levels govern hematopoietic tumor type and latency in transgenic mice.	MYC
16541139	10.1038/sj.leu.2404183	2006	Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation.	MYC
16675879	10.1155/2006/695262	2006	The CT-element of the c-myc gene does not predispose to chromosomal breakpoints in Burkitt's lymphoma.	MYC
16690525	10.1080/10428190500361128	2006	Expression of ice, bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma.	MYC
17001014	10.1073/pnas.0509988103	2006	Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.	MYC
15468060	10.1002/jcp.20229	2005	Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.	MYC
15716988	10.1038/sj.leu.2403661	2005	Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas.	MYC
15800668	10.1038/sj.leu.2403729	2005	G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.	MYC
16094360	10.1038/nature03845	2005	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.	MYC
16140957	10.1158/0008-5472.CAN-05-1581	2005	Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation.	MYC
16169462	10.1016/j.ccr.2005.08.005	2005	The great MYC escape in tumorigenesis.	MYC
14697225	10.1016/j.bbrc.2003.12.002	2004	Defective RNA-mediated c-myc gene silencing pathway in Burkitt's lymphoma.	MYC
15098029	10.1038/nm1042	2004	The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis.	MYC
15150404	10.1073/pnas.0402770101	2004	The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation.	MYC
15160911	10.1080/10428190310001607151	2004	The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome.	MYC
15191563	10.1111/j.0022-202X.2004.22720.x	2004	Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas.	MYC
15287031	10.1002/gcc.20063	2004	Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus.	MYC
12446731	10.1074/jbc.M206733200	2003	Guanine nucleotide exchange factor, Tiam1, directly binds to c-Myc and interferes with c-Myc-mediated apoptosis in rat-1 fibroblasts.	MYC
12553908	10.1016/s0092-8674(02)01284-9	2003	X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors.	MYC
12562237	10.5858/2003-127-208-EOPMOB	2003	Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.	MYC
12688321	10.1080/1042819021000047010	2003	Activation of protein kinase C enhances TNF-alpha-induced differentiation by preventing apoptosis via rapid up-regulation of c-Myc protein expression in HL-60 cells.	MYC
12808131	10.1073/pnas.1332764100	2003	A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.	MYC
11777933	10.1074/jbc.M111426200	2002	A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma.	MYC
12036888	10.1182/blood.v99.12.4554	2002	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	MYC
12149649	10.1038/sj.onc.1205640	2002	Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis.	MYC
12213716	10.1016/S0002-9440(10)64248-4	2002	The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.	MYC
11182042	10.3892/or.8.2.289	2001	c-myc gene mutation in gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma.	MYC
11443860	10.1007/978-3-642-56515-1_10	2001	EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.	MYC
11567024	10.1074/jbc.M106127200	2001	MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer.	MYC
9689053	10.1073/pnas.95.16.9172	1998	Identification of a large Myc-binding protein that contains RCC1-like repeats.	MYC
7642555	10.1074/jbc.270.32.18961	1995	c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.	MYC
8220424	10.1038/ng0993-56	1993	Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.	MYC
8247524		1993	Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential.	MYC
1597196	10.1111/j.1432-1033.1992.tb16964.x	1992	DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein.	MYC
3277717	10.1016/0092-8674(88)90507-7	1988	A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas.	MYC
3033665	10.1073/pnas.84.9.2824	1987	MYC oncogene involved in a t(8;22) chromosome translocation is not altered in its putative regulatory regions.	MYC
3540591	10.1128/mcb.6.10.3481-3489.1986	1986	Novel promoter upstream of the human c-myc gene and regulation of c-myc expression in B-cell lymphomas.	MYC
6419122	10.1038/306760a0	1984	Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.	MYC
6547209	10.1038/309592a0	1984	Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.	MYC
6304538	10.1038/303725a0	1983	Nucleotide sequence of cloned cDNA of human c-myc oncogene.	MYC
6321164	10.1002/j.1460-2075.1983.tb01749.x	1983	Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours.	MYC
6324175	10.1073/pnas.80.24.7476	1983	Activation of the c-myc gene by translocation: a model for translational control.	MYC
6414718	10.1016/0092-8674(83)90534-2	1983	The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.	MYC
